Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Biol. Res ; 48: 1-8, 2015. ilus, graf
Article in English | LILACS | ID: biblio-950801

ABSTRACT

BACKGROUND: Gliomas are the most common primary tumors in the central nervous system. Due to complicated signaling pathways involved in glioma progression, effective targets for treatment and biomarkers for prognosis prediction are still scant. RESULTS: In this study we revealed that a new microRNA (miR), the miR-221, was highly expressed in the glioma cells, and suppression of miR-221 resulted in decreased cellular proliferation, migration, and invasion in glioma cells. Mechanistic experiments validated that miR-221 participates in regulating glioma cells proliferation and invasion via suppression of a direct target gene, the Semaphorin 3B (SEMA3B). The rescue experiment with miR-221 and SEMA3B both knockdown results in significant reversion of miR-221 induced phenotypes. CONCLUSION: Taken together, our findings highlight an unappreciated role for miR-221 and SEMA3B in glioma.


Subject(s)
Humans , Brain Neoplasms/pathology , Membrane Glycoproteins/pharmacology , Apoptosis , Semaphorins/pharmacology , MicroRNAs/antagonists & inhibitors , Cell Proliferation , Glioma/pathology , Brain Neoplasms/metabolism , Membrane Glycoproteins/genetics , Signal Transduction , Gene Expression Regulation, Neoplastic , Cell Movement , Blotting, Western , Semaphorins/genetics , MicroRNAs/metabolism , Cell Line, Tumor , Real-Time Polymerase Chain Reaction , Glioma/metabolism , Luciferases/metabolism , Neoplasm Invasiveness
2.
Experimental & Molecular Medicine ; : 524-532, 2005.
Article in English | WPRIM | ID: wpr-191499

ABSTRACT

Receptor activator of NFkappaB ligand (RANKL) is known as a key regulator of osteoclastogenesis. However, the fact that fibroblasts and periodontal ligament cells express RANKL in response to bacterial substances, suggests that RANKL may have evolved as a part of the immunity to infection. As RANKL increases the survival and activity of dendritic cells, it may have similar effects on macrophages. To address this issue, we studied the effect of RANKL on various functions of macrophages using mouse bone marrow derived macrophages. RANKL enhanced the survival of macrophages and up-regulated the expression of CD86. RANKL-treated macrophages showed increased allogeneic T cell activation and phagocytic activity compared to control cells. In addition, RANKL increased the expression of TNFalpha, MCP-1, and IL-6 but not of IL-10, IL-12, IFN-gamma, and iNOS. Collectively, RANKL augmented the activity of macrophages especially as antigen presenting cells, suggesting its new role in immune regulation.


Subject(s)
Animals , Mice , Antigen-Presenting Cells/cytology , B7-2 Antigen/metabolism , Carrier Proteins/pharmacology , Cell Death/drug effects , Cell Survival/drug effects , Cells, Cultured , Cytokines/metabolism , Flow Cytometry , Histocompatibility Antigens Class II/metabolism , Inflammation Mediators , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/cytology , Membrane Glycoproteins/pharmacology , Mice, Inbred C57BL , Mice, Inbred ICR , Nitric Oxide Synthase Type II/metabolism , Phagocytosis/drug effects , T-Lymphocytes/immunology , Up-Regulation/drug effects
3.
Indian J Exp Biol ; 2002 Sep; 40(9): 995-1000
Article in English | IMSEAR | ID: sea-63409

ABSTRACT

Macrophage colony stimulating factor (M-CSF) and osteoclast differentiation factor (ODF) regulate osteoclastogenesis in vivo. Regulation of osteoclast development in vitro by these cytokines has been reported in the present study. Simultaneous addition of ODF and M-CSF during initiation of bone marrow culture inhibited osteoclastogenesis. However, delayed addition of ODF (three days after initiation of the culture) resulted in dramatic increase in phenotypically and functionally mature osteoclast cells. Delayed addition of ODF beyond day three decreased osteoclastogenesis. Further, removal of M-CSF as early as day three inhibited ODF-induced osteoclastogenesis. These studies provided evidence for the importance of co-ordinated regulation of osteoclastogenesis by M-CSF and ODF.


Subject(s)
Acid Phosphatase/metabolism , Actins/metabolism , Animals , Bone Marrow/physiology , Carrier Proteins/pharmacology , Cells, Cultured , Hematopoietic Stem Cells/cytology , Macrophage Colony-Stimulating Factor/pharmacology , Membrane Glycoproteins/pharmacology , Mice , Osteoclasts/cytology , Osteogenesis/drug effects , RANK Ligand , Receptor Activator of Nuclear Factor-kappa B , Recombinant Proteins/pharmacology , Tartrates/pharmacology , Time Factors
4.
Experimental & Molecular Medicine ; : 462-468, 2002.
Article in English | WPRIM | ID: wpr-13042

ABSTRACT

TNF-related apoptosis-inducing ligand (TRAIL/Apo- 2L), a newly identified member of the TNF family promotes apoptosis by binding to the transmembrane receptors (TRAIL-R1/DR4 and TRAIL-R2/ DR5). TRAIL known to activate NF-kappa B in number of tumor cells including A549 (wt p53) and NCI- H1299 (null p53) lung cancer cells exerts relatively selective cytotoxic affects to the human tumor cell lines without much effect on the normal cells. We set out to identify an agent that would sensitize lung cancer cells to TRAIL-induced apoptosis through inhibition of NF-kappa B activation. We found that triptolide, an oxygenated diterpene extracted and purified from the Chinese herb Tripterygium wilfordii sensitized A549 and NCI-H1299 cells to TRAIL-induced apoptosis through inhibition of NF-kappa B activation. Pretreatment with MG132 which is a well-known NF-kappa B inhibitor by blocking degradation of Ikappa B alpha also greatly sensitized lung cancer cells to TRAIL-induced apoptosis. Triptolide did not block DNA binding of NF-kappa B activated by TRAIL as in the case of TNF-alpha. It has been already proven that triptolide blocks transactivation of p65 which plays a key role in NF-kappa B activation. These observations suggest that triptolide may be a potentially useful drug to enhance TRAIL-induced tumor killing in lung cancer.


Subject(s)
Humans , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Line, Tumor , DNA/metabolism , Diterpenes/pharmacology , Lung Neoplasms/metabolism , Membrane Glycoproteins/pharmacology , NF-kappa B/antagonists & inhibitors , Phenanthrenes/pharmacology , Tumor Necrosis Factor-alpha/pharmacology
5.
Experimental & Molecular Medicine ; : 340-346, 2002.
Article in English | WPRIM | ID: wpr-203703

ABSTRACT

Macrophage colony-stimulating factor (M-CSF) is known as one of the factors essential for osteoclast development. In the present study, we examined effects of M-CSF on the apoptotic pathway of osteoclast precursors and their underlying molecular mechanisms. Osteoclast precursors underwent apoptosis in the absence of M-CSF, even in the presence of receptor activator of NF-kB ligand (RANKL). Active caspase-3 and -9 were detected in the osteoclast precursors and treatments of precursors with their specific inhibitors (Z- DEVD-FMK and Z-LEHD-FMK) decreased the apoptosis. M-CSF decreased apoptosis in a dose-dependent manner with decreasing in active caspases-3 and -9 levels and up-regulating Bcl-XL. Those effects of M-CSF on inhibiting apoptosis of osteoclasts precursor by regulating anti-apoptotic signals was more effective when combined with RANKL. These results demonstrate that M-CSF acts as a survival factor for the osteoclast precursors. Furthermore, it is believed that the apoptosis of osteoclast precursors may be involved in the activation of caspase-9 and that M-CSF may promote their survival through Bcl-XL-induced inhibition of caspase-9 activation.


Subject(s)
Animals , Female , Mice , Apoptosis/drug effects , Carrier Proteins/pharmacology , Caspases/antagonists & inhibitors , Cell Survival/drug effects , Cells, Cultured , Cysteine Proteinase Inhibitors/pharmacology , Enzyme Activation/drug effects , Macrophage Colony-Stimulating Factor/pharmacology , Membrane Glycoproteins/pharmacology , Mice, Inbred ICR , Oligopeptides/pharmacology , Osteoclasts/cytology , Proto-Oncogene Proteins c-bcl-2/drug effects , Stem Cells/cytology , Up-Regulation
6.
Indian J Pathol Microbiol ; 1993 Jul; 36(3): 260-4
Article in English | IMSEAR | ID: sea-74927

ABSTRACT

Assessment of 51 amoebic liver abscess cases for leukocyte migration inhibition factor released using membrane glycoprotein and detergent dissected membrane protein (DDMP) of axenic Entamoeba histolytica (NIH:200). Lymphokines release by T lymphocytes in response to purified amoebic membrane glycoprotein (PAMG) against whole amoebic lysate (WAL), dissect out protein against whole amoebic lysate and membrane glycoprotein against dissected protein was tested by leukocyte migration inhibition test on blood samples from proved amoebic liver abscess cases. A significant increase was noted in the release of lymphokines and 100% positivity was observed with both PAMG and DDMP compared to 78% with whole amoebic lysate. The difference between means leukocyte migration indices of the membrane glycoprotein and whole amoebic lysate, detergent dissected protein and whole amoebic lysate with regards to release LMIF were found to be highly significant (P < 0.001), (P < 0.005) respectively. But insignificant difference and very much similarity was noted between the means of membrane glycoprotein and dissect out protein sensitized T lymphocytes with regards to lymphokine release in vitro. This shows the patients had high degree of leukocyte sensitized to pure amoebic membrane glycoprotein and detergent dissected membrane protein compared to whole amoebic lysate. These findings indicate that detergent dissected protein has similar antigenicity with membrane glycoprotein in elicitation cell mediated immune response in amoebic liver abscess cases.


Subject(s)
Animals , Humans , Leukocyte Migration-Inhibitory Factors/analysis , Liver Abscess, Amebic/blood , Membrane Glycoproteins/pharmacology , Membrane Proteins/pharmacology , Protozoan Proteins/analysis
SELECTION OF CITATIONS
SEARCH DETAIL